What the FDA labels say about taking them together
Abatacept and adalimumab
Adalimumab's FDA label of October 21, 2025 names abatacept in its drug interactions section; the abatacept label PlainMeds reads does not name adalimumab. The adalimumab label: “DRUG INTERACTIONS Abatacept: Increased risk of serious infection.”
Check it at the source: the abatacept FDA label on DailyMed (effective November 13, 2025, E.R. Squibb & Sons, L.L.C.); the adalimumab FDA label on DailyMed (effective October 21, 2025).
What does the abatacept label say about adalimumab?
Abatacept's label (effective November 13, 2025) does not name adalimumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ORENCIA), E.R. Squibb & Sons, L.L.C., effective November 13, 2025 (SPL set 0836c6ac-ee37-5640-2fed-a3185a0b16eb), via openFDA; the full label on DailyMed
What does the adalimumab label say about abatacept?
Adalimumab label, drug interactionsIn clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF-blockers with anakinra or abatacept, with no added benefit; therefore, use of Adalimumab-adaz with abatacept or anakinra is not recommended in patients with RA [see Warnings and Precautions ( 5.7 , 5.11 )].
Adalimumab label, warnings and precautionsThe concomitant use of a TNF blocker and abatacept or anakinra was associated with a higher risk of serious infections in patients with rheumatoid arthritis (RA); therefore, the concomitant use of Adalimumab-adaz and these biologic products is not recommended in the treatment of patients with RA [see Warnings and Precautions ( 5.7 , 5.11 ) and Drug Interactions ( 7.2 )].
Humira label (AbbVie Inc., December 23, 2025), drug interactionsDRUG INTERACTIONS Abatacept: Increased risk of serious infection.
Source: FDA drug label (Humira, BLA125057), AbbVie Inc., effective December 23, 2025 (SPL set 608d4f0d-b19f-46d3-749a-7159aa5f933d), via openFDA
Source: FDA drug label (Adalimumab), Sandoz Inc, effective October 21, 2025 (SPL set 3468792f-63ef-4916-8ed1-8214f327d9dd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Abatacept | Adalimumab | |
|---|---|---|
| Labeled for | Rheumatoid arthritis | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1,469.23 per mL 125 mg/mL syringe | $1,587.82 per mL 40 mg/0.4 mL |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once